title: [Chronic hepatitis C. Epidemiology and therapeutic results in 255 cases].
abstract: A review of the statistics of the years 2003, 2004 to August 2005 has provided data corresponding to 255 patients that were diagnosed and included in the treatment protocol of chronic hepatitis C. Epidemiologically, the 2/1 man/woman ratio, mean age of 43 years and history of transfusion (transf.) in 18.6% are to be noted. Parenteral drug addicition (PDA) in 17% and alcoholism in 14.1%, of unknown origin in 58.74% of the cases. 79.05% corresponded to genotype 1, 4.74% to genotype 4, 14.22% to genotype 3, and 2.76% to genotype 2. Genotypes 1 and 4 were included in the treatment regime with PEG-Interferon alpha-2b + Ribavirin (with doses adjusted for weight) and those of genotype 3 and 2 in the regime with Interferon alpha 2b + Ribavirin. In 95 cases of Genotype 1 (87) and 4 (8), a sustained viral response (SVR) of 61.95% was obtained, with three drop-outs. In the 20 cases of genotypes 3 (17) and 2 (3), SVR was 85%, with no drop-outs. In the 20 cases of genotypes 3 (17) and 2 (3), SVR was 85%, with no drop-outs. The adjustment of treatment to body mass involved an economic savings per case amounting to 868.94 Euro. Finally, in 16 cases of Genotype 1, before treated with Interferon in monotherapy, a sustained viral response of 31.25% was obtained with combined therapy.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Virgen de la Torre y Area Sanitaria 1, Madrid. arturopm@teleline.es
authors.forename: A
authors.initials: A
authors.lastname: Pérez Mota
authors.forename: M A
authors.initials: MA
authors.lastname: Blanco Coronado
authors.forename: J
authors.initials: J
authors.lastname: Graus Morales
authors.forename: R
authors.initials: R
authors.lastname: Rodero Vázquez de Castro
authors.forename: C
authors.initials: C
authors.lastname: Pérez Muñoz
authors.forename: J L
authors.initials: JL
authors.lastname: de Vicente Bach
authors.forename: C
authors.initials: C
authors.lastname: Villalgordo Aparicio
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000187:drug effects / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents